Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 77.26% is in line with its 5-year average of 79.38%, near the low end of its 5-year range (75.17%–83.76%).
0.58% below its 12-month average of 77.71%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 77.11%.
GROSS MARGIN
77.26%
GROSS MARGIN AVG TTM
77.71%
GROSS MARGIN AVG 3Y
79.85%
GROSS MARGIN AVG 5Y
79.38%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.58%
CURRENT VS 3Y AVG
-3.24%
CURRENT VS 5Y AVG
-2.67%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+86.71%
vs the sector median at left
Castle Biosciences, Inc.
Market Cap
$1.02B
Gross Margin
77.26%
TTM Avg
77.71%
3Y Avg
79.85%
5Y Avg
79.38%
Market Cap
$1.02B
Gross Margin
79.71%
TTM Avg
80.13%
3Y Avg
81.57%
5Y Avg
-49.18%
Market Cap
$1.03B
Gross Margin
11.80%
TTM Avg
10.80%
3Y Avg
10.72%
5Y Avg
10.72%
Market Cap
$1.04B
Gross Margin
53.74%
TTM Avg
53.23%
3Y Avg
56.54%
5Y Avg
58.23%
Market Cap
$998.69M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
16.67%
Market Cap
$996.65M
Gross Margin
63.74%
TTM Avg
62.39%
3Y Avg
56.59%
5Y Avg
42.69%
Market Cap
$1.05B
Gross Margin
73.53%
TTM Avg
70.13%
3Y Avg
70.04%
5Y Avg
68.74%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Castle Biosciences, Inc. (CSTL) | $1.02B | 77.26% | 77.71% | 79.85% | 79.38% |
| Janux Therapeutics, Inc. (JANX)vs › | $1.02B | 79.71% | 80.13% | 81.57% | -49.18% |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.03B | 11.80% | 10.80% | 10.72% | 10.72% |
| Immatics N.V. (IMTX)vs › | $1.01B | 100.00% | 100.00% | 100.00% | 64.23% |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.04B | 53.74% | 53.23% | 56.54% | 58.23% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $998.69M | 0.00% | 0.00% | 0.00% | 16.67% |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $996.65M | 63.74% | 62.39% | 56.59% | 42.69% |
| Vor Biopharma Inc. (VOR)vs › | $992.14M | 0.00% | 0.00% | 0.00% | 0.00% |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | 73.53% | 70.13% | 70.04% | 68.74% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $982.46M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
77.3%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 77.11% |
| 2026-03-31 | 75.46% |
| 2025-12-31 | 78.95% |
| 2025-09-30 | 77.48% |
| 2025-06-30 | 79.55% |
| 2025-03-31 | 81.38% |
| 2024-12-31 | 81.25% |
| 2024-09-30 | 81.80% |
| 2024-06-30 | 83.31% |
| 2024-03-31 | 80.96% |
| 2023-12-31 | 81.21% |
| 2023-09-30 | 81.59% |
| 2023-06-30 | 77.94% |
| 2023-03-31 | 75.78% |
| 2022-12-31 | 75.17% |
| 2022-09-30 | 76.06% |
| 2022-06-30 | 77.94% |
| 2022-03-31 | 77.86% |
| 2021-12-31 | 81.64% |
| 2021-09-30 | 80.83% |
| 2021-06-30 | 83.76% |
| 2021-03-31 | 86.73% |
| 2020-12-31 | 84.55% |
| 2020-09-30 | 83.74% |
| 2020-06-30 | 83.12% |
| 2020-03-31 | 86.27% |
| 2019-12-31 | 88.60% |
| 2019-09-30 | 88.43% |
| 2019-06-30 | 81.44% |
| 2019-03-31 | 81.67% |
| 2018-12-31 | 88.05% |
| 2018-09-30 | 63.61% |
| 2018-06-30 | 66.66% |
| 2018-03-31 | 65.75% |
